NDA 050794 · Bristol-Myers
Vidaza
Azacitidine · Intravenous, Subcutaneous · Nucleoside Metabolic Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
May 19, 2004
Approved uses
4
Original approval plus efficacy supplements
Registered trials
1,227
154 Phase 3, 243 recruiting
FAERS reports
29,331
28,307 serious, 10,819 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 29, 2024.
VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of: • Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1.1 ) • Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML). ( 1.2 ) 1.1 Myelodysplastic Syndromes (MDS) VIDAZA ® is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). 1.2 Juvenile Myelomonocytic Leukemia (JMML) VIDAZA is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML.
Mechanism: VIDAZA is a pyrimidine nucleoside analog of cytidine. VIDAZA is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including cancer cells that are no longer...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 20, 2022 Supplement 34 · Efficacy · priority review OrphanLabelLetter
- Aug 20, 2008 Supplement 11 · Efficacy · priority review LabelLetter
- Jan 26, 2007 Supplement 5 · Efficacy Label
- May 19, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
- VIDAZA · AZACITIDINE 100MG/VIAL · POWDER, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Azacitidine" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsPivotal-lookingStatus unknown
Cardiff UniversityAcademic, hospital or other
NCT02272478 · 1,600 participants (planned) · Start Oct 30, 2014 · Primary completion Feb 2021
Drug: Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine and 4 more · For: Acute Myeloid Leukaemia; Myelodysplastic Syndrome
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 87 sites in all
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPivotal-lookingRecruiting
Kura Oncology, Inc.Industry
NCT07007312 · 1,300 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 2031
Drug: Ziftomenib; Placebo and 4 more · For: Acute Myeloid Leukemia (AML)
Sites: Gilbert, Arizona; Clovis, California; La Jolla, California · 141 sites in all
- Genotype-guided Treatment in DLBCLPivotal-lookingStatus unknown
Ruijin HospitalAcademic, hospital or other
NCT05351346 · 1,100 participants (planned) · Start Jun 1, 2022 · Primary completion Jun 1, 2026
Drug: Rituximab; Cyclophosphamide and 6 more · For: Diffuse Large B Cell Lymphoma
Sites: Shanghai, China
- HVA vs IA/DA or VA in the Treatment of ND HR-AMLPivotal-lookingRecruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT06810791 · 876 participants (planned) · Start Jan 1, 2025 · Primary completion Jun 30, 2026
Drug: HVA; VA and 1 more · For: Newly Diagnosed Acute Myeloid Leukemia With High Risk
Sites: Guangzhou, China
- SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionPivotal-lookingCompleted
Astex Pharmaceuticals, Inc.Industry
NCT02348489 · 815 participants · Start Mar 19, 2015 · Primary completion May 31, 2018
Drug: SGI-110 (guadecitabine); Treatment Choice · For: Leukemia, Myeloid, Acute
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 135 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3,321
- febrile neutropenia3,027
- acute myeloid leukaemia2,211
- pneumonia2,017
- neutropenia1,996
- off label use1,992
- myelosuppression1,806
- pyrexia1,687
- thrombocytopenia1,617
- anaemia1,438
- platelet count decreased1,279
- sepsis1,266
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 55 |
| 2006 | 44 |
| 2007 | 43 |
| 2008 | 93 |
| 2009 | 378 |
| 2010 | 597 |
| 2011 | 818 |
| 2012 | 1,084 |
| 2013 | 921 |
| 2014 | 1,106 |
| 2015 | 1,042 |
| 2016 | 876 |
| 2017 | 1,173 |
| 2018 | 1,371 |
| 2019 | 1,731 |
| 2020 | 1,790 |
| 2021 | 2,496 |
| 2022 | 3,148 |
| 2023 | 2,842 |
| 2024 | 2,725 |
| 2025 | 2,975 |
| 2026 | 2,005 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 16, 2026
Vidaza, Injection, 100 mg (NDC 59572-102-01).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD, Jonas BA, Pullarkat V, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW, Jonas BA, Pullarkat V, et al. · Am J Hematol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
Montesinos P, Recher C, Vives S, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Fathi AT, Perl AE, Fell GG, et al. · N Engl J Med 2026 · Multicenter Study, Randomized Controlled Trial
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Zeidner JF, Lin TL, Welkie RL, et al. · J Clin Oncol 2025 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.